Department of Medical Oncology, Barretos Cancer Hospital bCenter for Evidence-Based Oncology, Faculty of Medical Sciences, University of Campinas cDepartment of Radiology, Barretos Cancer Hospital, Brazil.
Anticancer Drugs. 2011 Jun;22 Suppl 2:S15-7. doi: 10.1097/01.cad.0000398728.45590.11.
Bevacizumab-containing treatment is one of the approved first-line options for the management of metastatic colorectal cancer (CRC). Carcino-embryonic antigen (CEA) is a reasonable tumour marker for monitoring the efficacy of treatment. We report here a case of a 58-year-old male patient with metastatic CRC. He received first-line chemotherapy consisting of the mFOLFOX6 regimen plus bevacizumab. Initially he had an increase in CEA after which the level reduced, suggesting the occurrence of a CEA flare. The patient experienced a good response to therapy. In recent literature, CEA flare was identified as a good predictor of response to first-line chemotherapy.
贝伐珠单抗为基础的治疗是转移性结直肠癌（CRC）的一线治疗方案之一。癌胚抗原（CEA）是监测治疗效果的合理肿瘤标志物。我们在此报告了一例转移性结直肠癌 58 岁男性患者。他接受了一线化疗，方案为 mFOLFOX6 联合贝伐珠单抗。起初他的 CEA 升高，随后水平降低，提示发生 CEA 爆发。患者对治疗有良好的反应。在最近的文献中，CEA 爆发被认为是一线化疗反应的良好预测指标。
